Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Current Assets (2018 - 2025)

Summit Therapeutics' Current Assets history spans 8 years, with the latest figure at $246.5 million for Q3 2025.

  • For Q3 2025, Current Assets fell 49.73% year-over-year to $246.5 million; the TTM value through Sep 2025 reached $246.5 million, down 49.73%, while the annual FY2024 figure was $423.8 million, 123.36% up from the prior year.
  • Current Assets reached $246.5 million in Q3 2025 per SMMT's latest filing, down from $309.2 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $656.7 million in Q4 2022 to a low of $79.4 million in Q2 2022.
  • Average Current Assets over 5 years is $243.2 million, with a median of $205.0 million recorded in 2023.
  • Peak YoY movement for Current Assets: soared 574.85% in 2022, then plummeted 71.11% in 2023.
  • A 5-year view of Current Assets shows it stood at $97.3 million in 2021, then skyrocketed by 574.85% to $656.7 million in 2022, then tumbled by 71.11% to $189.7 million in 2023, then skyrocketed by 123.36% to $423.8 million in 2024, then tumbled by 41.84% to $246.5 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Current Assets are $246.5 million (Q3 2025), $309.2 million (Q2 2025), and $370.8 million (Q1 2025).